Vericiguat after recent worsening HFrEF — ACC/AHA · 2022 recommendation
2022 AHA/ACC/HFSA heart failure guideline
For selected high-risk HFrEF patients with recent worsening despite guideline-directed medical therapy, vericiguat may be considered to reduce heart-failure hospitalization and cardiovascular death.
Class of Recommendation
Class 2b
Level of Evidence
Level B-R
Last source-check date
2026-08-23
Exact source location
Section 7.3.9.3, ‘Soluble Guanylyl Cyclase Stimulators’, p. e941; recommendation table
Prepared source-record governance
This record is prepared from a stored source. It is not labelled reviewer-verified because named reviewer provenance has not been documented.
- Clinical reviewer
- Not yet documented.
- Reviewer credentials
- Not yet documented.
- Last source-check date
- 2026-08-23
- Second-review status
- Not yet documented.
- Conflict-of-interest declaration
- Not yet documented.
- Source publication date
- Not yet documented.
- Source access date
- Not yet documented.
- Record version
- Not yet documented.
- Change history
- Not yet documented.
- Next review date
- Not yet documented.
Verification status & editorial record
Status: Prepared source record — reviewer provenance not documented.
Last source-check: 2026-08-23
No formally approved public metadata is currently available for a named reviewer, second-review status, conflict declaration, publication or access date, version history, or next review date for this record.
Verification boundary: This concise reference is limited to a prepared source recommendation. Verify the official document, local protocol, and patient context before application.